Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

IMPORTANCE: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. OBJECTIVE: To describe clinical outcomes for women with a high RS who received adjuvant c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Sparano, Joseph A., Gray, Robert J., Makower, Della F., Albain, Kathy S., Saphner, Thomas J., Badve, Sunil S, Wagner, Lynne I., Kaklamani, Virginia G., Keane, Maccon M., Gomez, Henry L., Reddy, Pavan S., Goggins, Timothy F., Mayer, Ingrid A., Toppmeyer, Deborah L., Brufsky, Adam M., Goetz, Matthew P., Berenberg, Jeffrey L., Mahalcioiu, Catalin, Desbiens, Christine, Hayes, Daniel F., Dees, Elizabeth C., Geyer, Charles E., Olson, John A., Wood, William C, Lively, Tracy, Paik, Soonmyung, Ellis, Matthew J., Abrams, Jeffrey, Sledge, George W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777230/
https://ncbi.nlm.nih.gov/pubmed/31566680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.4794
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados